相关实验视频

Updated: Jul 5, 2025

Quantification of Hypopigmentation Activity In Vitro

Quantification of Hypopigmentation Activity In Vitro

Published on: March 6, 2019

锡林TM作为铁酶抑制剂和抗色剂

Joanna Cytarska¹, Joanna Szulc², Dominika Kołodziej-Sobczak¹

¹Department of Chemical Technology and Pharmaceuticals, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Jurasza 2, 85-089 Bydgoszcz, Poland.

|January 19, 2024

概括

锡林TM显示出显著的铁酶抑制活性,表现优于 Askorbic 酸. 这种生物基化合物为食品工业提供了作为安全抗色剂的潜力.

科学领域:

食品科学食品科学食品科学
生物化学生物化学
酶学是一种酶学.

背景情况:

铁酶途径在酶性食品化过程中至关重要,导致腐烂,营养价值降低和保质期缩短.
确定安全的生物基铁酶抑制剂对于农业和食品工业来说至关重要,以保持食品质量.

研究的目的:

调查CyreneTM的铁酶抑制潜力.
为了比较CyreneTM与 Askorbic 酸作为铁酶抑制剂的疗效.
为了阐明CyreneTM与铁酶的结合方式.

主要方法:

进行了酶抑制测定,以确定CyreneTM和酸的IC50值.
进行了分子对接或结合模式研究,以分析CyreneTM和铁酶之间的相互作用.

主要成果:

锡林TM表现出显著的铁酶抑制活性,IC50为268.2μM.
这种活性是酸的1.44倍 (IC50:386.5μM).
结合性研究表明,CyreneTM通过其碳基氧和基基团与铁酶的铜离子协调,这表明它与其他抑制剂具有类似的结合方式.

结论:

CyreneTM是一种强效的铁酶抑制剂,具有有前途的抗色特性.
它的生物基性质和与其他抑制剂相比较的结合方式表明它有可能成为食品保存的安全替代品.
对CyreneTM的进一步研究可能会导致创新的解决方案,以延长食品的保质期并保持质量.

关键词:

抗色剂是一种抗色剂.关联协调关联协调关联协调基利尼和基利尼人.动力学模拟的动力学模拟.分子对接是分子对接.铁酶抑制剂铁酶抑制剂

更多相关视频

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress

Published on: August 31, 2015

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

相关概念视频

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...